Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01610284




Registration number
NCT01610284
Ethics application status
Date submitted
11/05/2012
Date registered
4/06/2012
Date last updated
25/08/2020

Titles & IDs
Public title
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Scientific title
A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Secondary ID [1] 0 0
2011-005524-17
Secondary ID [2] 0 0
CBKM120F2302
Universal Trial Number (UTN)
Trial acronym
BELLE-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fulvestrant
Treatment: Drugs - BKM120
Treatment: Drugs - BKM120 matching placebo

Experimental: BKM120 100mg + Fulvestrant - BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.

Placebo comparator: Placebo + Fulvestrant - BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.


Treatment: Drugs: Fulvestrant
Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)

Treatment: Drugs: BKM120
BKM120 100 mg once daily

Treatment: Drugs: BKM120 matching placebo
BKM120 matching placebo, once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort
Timepoint [1] 0 0
Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years
Secondary outcome [1] 0 0
Overall Survival (OS) - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort
Timepoint [1] 0 0
Every 3 months following end of treatment visit, assessed for approximately 5 years
Secondary outcome [2] 0 0
Overall Response Rate (ORR) - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort
Timepoint [2] 0 0
From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 5 years
Secondary outcome [3] 0 0
Clinical Benefit Rate (CBR) - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort
Timepoint [3] 0 0
From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 5 years
Secondary outcome [4] 0 0
Number of Participants With On-Treatments Adverse Events, Serious Adverse Events and Deaths
Timepoint [4] 0 0
From first dose of study treatment to 30 days after last dose of study treatment, assessed for approximately 5 years
Secondary outcome [5] 0 0
Plasma Concentration-time Profiles of BKM120 in Combination With Fulvestrant at Cycle 2 Day 1
Timepoint [5] 0 0
Cycle2 Day1 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours post-dose). Each cycle is 28 days.
Secondary outcome [6] 0 0
Predose Trough Concentration-time Profile of BKM120 in Combination With Fulvestrant Over Time - Pharmacokinetic Analysis Set (PAS)
Timepoint [6] 0 0
Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1. Each cycle is 28 days.
Secondary outcome [7] 0 0
Median Time to Definitive Deterioration of the ECOG Performance Status - Full Analysis Set (FAS)
Timepoint [7] 0 0
Up to approx 27 months
Secondary outcome [8] 0 0
Health-related Quality of Life (HRQoL):Time to 10% Definitive Deterioration in the Global Health Status/Quality of Life Per EORTC-QLQ-C30
Timepoint [8] 0 0
Cycle 1 day 1, cycle 1 day 15, 6 weeks after randomisation and then every 8 weeks until end of treatment

Eligibility
Key inclusion criteria
Key

* Locally advanced or metastatic breast cancer
* HER2-negative and hormone receptor-positive status (common breast cancer classification tests)
* Postmenopausal woman
* A tumor sample must be shipped to a Novartis designated laboratory for identification of biomarkers (PI3K activation status)
* Progression or recurrence of breast cancer while on or after aromatase inhibitor treatment
* Measurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1
* Adequate bone marrow and organ function defined by laboratory values

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitor or fulvestrant
* More than one prior chemotherapy line for metastatic disease
* Symptomatic brain metastases
* Increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent
* Active heart (cardiac) disease as defined in the protocol
* Certain scores on an anxiety and depression mood questionnaires

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/08/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/04/2019
Sample size
Target
Accrual to date
Final
1147
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Sydney
Recruitment hospital [2] 0 0
Novartis Investigative Site - Woollongong
Recruitment hospital [3] 0 0
Novartis Investigative Site - South Brisbane
Recruitment hospital [4] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [5] 0 0
Novartis Investigative Site - Melbourne
Recruitment hospital [6] 0 0
Novartis Investigative Site - Murdoch
Recruitment hospital [7] 0 0
Novartis Investigative Site - Nedlands
Recruitment postcode(s) [1] 0 0
2060 - Sydney
Recruitment postcode(s) [2] 0 0
2500 - Woollongong
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
3000 - Melbourne
Recruitment postcode(s) [6] 0 0
6150 - Murdoch
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
West Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Tucuman
Country [31] 0 0
Argentina
State/province [31] 0 0
Viedma
Country [32] 0 0
Austria
State/province [32] 0 0
Linz
Country [33] 0 0
Austria
State/province [33] 0 0
Salzburg
Country [34] 0 0
Austria
State/province [34] 0 0
Wien
Country [35] 0 0
Belgium
State/province [35] 0 0
Brussel
Country [36] 0 0
Belgium
State/province [36] 0 0
Bruxelles
Country [37] 0 0
Belgium
State/province [37] 0 0
Charleroi
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Liege
Country [40] 0 0
Belgium
State/province [40] 0 0
Namur
Country [41] 0 0
Belgium
State/province [41] 0 0
Wilrijk
Country [42] 0 0
Brazil
State/province [42] 0 0
MG
Country [43] 0 0
Brazil
State/province [43] 0 0
PR
Country [44] 0 0
Brazil
State/province [44] 0 0
RN
Country [45] 0 0
Brazil
State/province [45] 0 0
RS
Country [46] 0 0
Brazil
State/province [46] 0 0
SP
Country [47] 0 0
Canada
State/province [47] 0 0
Alberta
Country [48] 0 0
Canada
State/province [48] 0 0
British Columbia
Country [49] 0 0
Canada
State/province [49] 0 0
Nova Scotia
Country [50] 0 0
Canada
State/province [50] 0 0
Ontario
Country [51] 0 0
Canada
State/province [51] 0 0
Quebec
Country [52] 0 0
Canada
State/province [52] 0 0
Saskatchewan
Country [53] 0 0
China
State/province [53] 0 0
Heilongjiang
Country [54] 0 0
China
State/province [54] 0 0
Hunan
Country [55] 0 0
China
State/province [55] 0 0
Jiangsu
Country [56] 0 0
China
State/province [56] 0 0
Liaoning
Country [57] 0 0
China
State/province [57] 0 0
Shanghai
Country [58] 0 0
China
State/province [58] 0 0
Sichuan
Country [59] 0 0
China
State/province [59] 0 0
Zhejiang
Country [60] 0 0
China
State/province [60] 0 0
Beijing
Country [61] 0 0
China
State/province [61] 0 0
Guangzhou
Country [62] 0 0
Czechia
State/province [62] 0 0
Czech Republic
Country [63] 0 0
Czechia
State/province [63] 0 0
CZE
Country [64] 0 0
Czechia
State/province [64] 0 0
Brno
Country [65] 0 0
France
State/province [65] 0 0
Alpes Maritimes
Country [66] 0 0
France
State/province [66] 0 0
Cote D Or
Country [67] 0 0
France
State/province [67] 0 0
Loire
Country [68] 0 0
France
State/province [68] 0 0
Angers Cedex 02
Country [69] 0 0
France
State/province [69] 0 0
Avignon Cedex
Country [70] 0 0
France
State/province [70] 0 0
Besancon cedex
Country [71] 0 0
France
State/province [71] 0 0
Bordeaux
Country [72] 0 0
France
State/province [72] 0 0
Caen Cedex
Country [73] 0 0
France
State/province [73] 0 0
Clermont-Ferrand
Country [74] 0 0
France
State/province [74] 0 0
Le Mans Cedex
Country [75] 0 0
France
State/province [75] 0 0
Lille Cedex
Country [76] 0 0
France
State/province [76] 0 0
Montpellier Cedex 5
Country [77] 0 0
France
State/province [77] 0 0
Paris
Country [78] 0 0
France
State/province [78] 0 0
Rouen Cedex 1
Country [79] 0 0
France
State/province [79] 0 0
Saint-Herblain Cédex
Country [80] 0 0
France
State/province [80] 0 0
Strasbourg cedex
Country [81] 0 0
France
State/province [81] 0 0
Toulouse Cedex 9
Country [82] 0 0
France
State/province [82] 0 0
Villejuif Cedex
Country [83] 0 0
Germany
State/province [83] 0 0
Hessen
Country [84] 0 0
Germany
State/province [84] 0 0
North Rhine-westphalia
Country [85] 0 0
Germany
State/province [85] 0 0
Schleswig-holstein
Country [86] 0 0
Germany
State/province [86] 0 0
Essen
Country [87] 0 0
Germany
State/province [87] 0 0
Hamburg
Country [88] 0 0
Germany
State/province [88] 0 0
Hannover
Country [89] 0 0
Germany
State/province [89] 0 0
Heidelberg
Country [90] 0 0
Germany
State/province [90] 0 0
Kiel
Country [91] 0 0
Germany
State/province [91] 0 0
Magdeburg
Country [92] 0 0
Germany
State/province [92] 0 0
Mainz
Country [93] 0 0
Germany
State/province [93] 0 0
Mannheim
Country [94] 0 0
Germany
State/province [94] 0 0
Mühlhausen
Country [95] 0 0
Germany
State/province [95] 0 0
München
Country [96] 0 0
Germany
State/province [96] 0 0
Saarbruecken
Country [97] 0 0
Germany
State/province [97] 0 0
Velbert
Country [98] 0 0
Germany
State/province [98] 0 0
Wuerzburg
Country [99] 0 0
Greece
State/province [99] 0 0
GR
Country [100] 0 0
Greece
State/province [100] 0 0
Athens
Country [101] 0 0
Greece
State/province [101] 0 0
Heraklion Crete
Country [102] 0 0
Greece
State/province [102] 0 0
Patras
Country [103] 0 0
Hungary
State/province [103] 0 0
Budapest
Country [104] 0 0
Hungary
State/province [104] 0 0
Debrecen
Country [105] 0 0
Hungary
State/province [105] 0 0
Miskolc
Country [106] 0 0
Hungary
State/province [106] 0 0
Szolnok
Country [107] 0 0
Israel
State/province [107] 0 0
Haifa
Country [108] 0 0
Israel
State/province [108] 0 0
Jerusalem
Country [109] 0 0
Israel
State/province [109] 0 0
Petach Tikva
Country [110] 0 0
Israel
State/province [110] 0 0
Ramat Gan
Country [111] 0 0
Israel
State/province [111] 0 0
Tel Aviv
Country [112] 0 0
Italy
State/province [112] 0 0
CN
Country [113] 0 0
Italy
State/province [113] 0 0
CR
Country [114] 0 0
Italy
State/province [114] 0 0
CZ
Country [115] 0 0
Italy
State/province [115] 0 0
FC
Country [116] 0 0
Italy
State/province [116] 0 0
FI
Country [117] 0 0
Italy
State/province [117] 0 0
LU
Country [118] 0 0
Italy
State/province [118] 0 0
MC
Country [119] 0 0
Italy
State/province [119] 0 0
MI
Country [120] 0 0
Italy
State/province [120] 0 0
PI
Country [121] 0 0
Italy
State/province [121] 0 0
PN
Country [122] 0 0
Italy
State/province [122] 0 0
RM
Country [123] 0 0
Italy
State/province [123] 0 0
RN
Country [124] 0 0
Italy
State/province [124] 0 0
TO
Country [125] 0 0
Italy
State/province [125] 0 0
VE
Country [126] 0 0
Italy
State/province [126] 0 0
Bologna
Country [127] 0 0
Italy
State/province [127] 0 0
Napoli
Country [128] 0 0
Japan
State/province [128] 0 0
Aichi
Country [129] 0 0
Japan
State/province [129] 0 0
Chiba
Country [130] 0 0
Japan
State/province [130] 0 0
Fukuoka
Country [131] 0 0
Japan
State/province [131] 0 0
Gunma
Country [132] 0 0
Japan
State/province [132] 0 0
Hokkaido
Country [133] 0 0
Japan
State/province [133] 0 0
Kanagawa
Country [134] 0 0
Japan
State/province [134] 0 0
Kumamoto
Country [135] 0 0
Japan
State/province [135] 0 0
Kyoto
Country [136] 0 0
Japan
State/province [136] 0 0
Osaka
Country [137] 0 0
Japan
State/province [137] 0 0
Tokyo
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Gyeonggi-do
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Seocho Gu
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Seoul
Country [141] 0 0
Netherlands
State/province [141] 0 0
Nijmegen
Country [142] 0 0
Peru
State/province [142] 0 0
Lima
Country [143] 0 0
Poland
State/province [143] 0 0
Kraków
Country [144] 0 0
Poland
State/province [144] 0 0
Olsztyn
Country [145] 0 0
Poland
State/province [145] 0 0
Warszawa
Country [146] 0 0
Russian Federation
State/province [146] 0 0
Moscow
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Nizhniy Novgorod
Country [148] 0 0
Russian Federation
State/province [148] 0 0
St Petersburg
Country [149] 0 0
Russian Federation
State/province [149] 0 0
St- Petersburg
Country [150] 0 0
Singapore
State/province [150] 0 0
Singapore
Country [151] 0 0
Slovakia
State/province [151] 0 0
Slovak Republic
Country [152] 0 0
Slovakia
State/province [152] 0 0
Kosice
Country [153] 0 0
South Africa
State/province [153] 0 0
Johannesburg
Country [154] 0 0
South Africa
State/province [154] 0 0
Parktown
Country [155] 0 0
Spain
State/province [155] 0 0
Alicante
Country [156] 0 0
Spain
State/province [156] 0 0
Andalucia
Country [157] 0 0
Spain
State/province [157] 0 0
Asturias
Country [158] 0 0
Spain
State/province [158] 0 0
Castilla La Mancha
Country [159] 0 0
Spain
State/province [159] 0 0
Catalunya
Country [160] 0 0
Spain
State/province [160] 0 0
Cataluña
Country [161] 0 0
Spain
State/province [161] 0 0
Comunidad Valenciana
Country [162] 0 0
Spain
State/province [162] 0 0
Las Palmas De Gran Canaria
Country [163] 0 0
Spain
State/province [163] 0 0
Madrid
Country [164] 0 0
Spain
State/province [164] 0 0
Murcia
Country [165] 0 0
Spain
State/province [165] 0 0
Barcelona
Country [166] 0 0
Spain
State/province [166] 0 0
Zaragoza
Country [167] 0 0
Switzerland
State/province [167] 0 0
Bellinzona
Country [168] 0 0
Switzerland
State/province [168] 0 0
Genève
Country [169] 0 0
Switzerland
State/province [169] 0 0
Zuerich
Country [170] 0 0
Taiwan
State/province [170] 0 0
Kaohsiung
Country [171] 0 0
Taiwan
State/province [171] 0 0
Taichung
Country [172] 0 0
Taiwan
State/province [172] 0 0
Taipei
Country [173] 0 0
Thailand
State/province [173] 0 0
Bangkok
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Cornwall
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Bournemouth
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Derby
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Leicester
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Liverpool
Country [179] 0 0
United Kingdom
State/province [179] 0 0
London
Country [180] 0 0
United Kingdom
State/province [180] 0 0
Manchester
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal women with hormone Receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), locally advanced or metastatic breast cancer (MBC) whose disease has progressed on or after aromatase inhibitor (AI) treatment.
Trial website
https://clinicaltrials.gov/study/NCT01610284
Trial related presentations / publications
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortes J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaer S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.
Baselga J, Im SA, Iwata H, Cortes J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. Erratum In: Lancet Oncol. 2019 Feb;20(2):e71-e72. doi: 10.1016/S1470-2045(19)30015-4.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01610284